956 related articles for article (PubMed ID: 18620092)
21. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
22. Multiple roles for the receptor tyrosine kinase axl in tumor formation.
Holland SJ; Powell MJ; Franci C; Chan EW; Friera AM; Atchison RE; McLaughlin J; Swift SE; Pali ES; Yam G; Wong S; Lasaga J; Shen MR; Yu S; Xu W; Hitoshi Y; Bogenberger J; Nör JE; Payan DG; Lorens JB
Cancer Res; 2005 Oct; 65(20):9294-303. PubMed ID: 16230391
[TBL] [Abstract][Full Text] [Related]
23. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
24. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
Gajiwala KS; Grodsky N; Bolaños B; Feng J; Ferre R; Timofeevski S; Xu M; Murray BW; Johnson TW; Stewart A
J Biol Chem; 2017 Sep; 292(38):15705-15716. PubMed ID: 28724631
[TBL] [Abstract][Full Text] [Related]
25. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
26. Differential regulation of hepatic physiology and injury by the TAM receptors Axl and Mer.
Zagórska A; Través PG; Jiménez-García L; Strickland JD; Oh J; Tapia FJ; Mayoral R; Burrola P; Copple BL; Lemke G
Life Sci Alliance; 2020 Aug; 3(8):. PubMed ID: 32571802
[TBL] [Abstract][Full Text] [Related]
27. Targeting Gas6/TAM in cancer cells and tumor microenvironment.
Wu G; Ma Z; Cheng Y; Hu W; Deng C; Jiang S; Li T; Chen F; Yang Y
Mol Cancer; 2018 Jan; 17(1):20. PubMed ID: 29386018
[TBL] [Abstract][Full Text] [Related]
28. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
29. Axl kinase as a key target for oncology: focus on small molecule inhibitors.
Feneyrolles C; Spenlinhauer A; Guiet L; Fauvel B; Daydé-Cazals B; Warnault P; Chevé G; Yasri A
Mol Cancer Ther; 2014 Sep; 13(9):2141-8. PubMed ID: 25139999
[TBL] [Abstract][Full Text] [Related]
30. Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system.
Prieto AL; Weber JL; Lai C
J Comp Neurol; 2000 Sep; 425(2):295-314. PubMed ID: 10954847
[TBL] [Abstract][Full Text] [Related]
31. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
32. TAM kinase signaling is indispensable for proper skeletal muscle regeneration in mice.
Al-Zaeed N; Budai Z; Szondy Z; Sarang Z
Cell Death Dis; 2021 Jun; 12(6):611. PubMed ID: 34120143
[TBL] [Abstract][Full Text] [Related]
33. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield I; Farnworth S
Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathways: MERTK signaling in cancer.
Cummings CT; Deryckere D; Earp HS; Graham DK
Clin Cancer Res; 2013 Oct; 19(19):5275-80. PubMed ID: 23833304
[TBL] [Abstract][Full Text] [Related]
35. TAM receptors are pleiotropic inhibitors of the innate immune response.
Rothlin CV; Ghosh S; Zuniga EI; Oldstone MB; Lemke G
Cell; 2007 Dec; 131(6):1124-36. PubMed ID: 18083102
[TBL] [Abstract][Full Text] [Related]
36. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.
Paccez JD; Vogelsang M; Parker MI; Zerbini LF
Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974
[TBL] [Abstract][Full Text] [Related]
37. Macrophage regulation by Tyro 3 family receptors.
Lemke G; Lu Q
Curr Opin Immunol; 2003 Feb; 15(1):31-6. PubMed ID: 12495730
[No Abstract] [Full Text] [Related]
38. TAM Receptor Tyrosine Kinases in Cancer Drug Resistance.
Vouri M; Hafizi S
Cancer Res; 2017 Jun; 77(11):2775-2778. PubMed ID: 28526769
[TBL] [Abstract][Full Text] [Related]
39. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
[TBL] [Abstract][Full Text] [Related]
40. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
